| scholarly article | Q13442814 |
| review article | Q7318358 |
| P6179 | Dimensions Publication ID | 1000320841 |
| P356 | DOI | 10.1007/S10620-010-1187-4 |
| P932 | PMC publication ID | 2890301 |
| P698 | PubMed publication ID | 20300841 |
| P5875 | ResearchGate publication ID | 42346389 |
| P2093 | author name string | Wael El-Rifai | |
| Laura W Goff | |||
| A Bapsi Chakravarthy | |||
| Kaushik Mukherjee | |||
| P2860 | cites work | Preoperative chemotherapy for resectable thoracic esophageal cancer | Q24245213 |
| Gastric cancers overexpress DARPP-32 and a novel isoform, t-DARPP | Q28215053 | ||
| Gains and Amplifications of c-myc, EGFR, and 20.q13 Loci in the No Dysplasia-Dysplasia-Adenocarcinoma Sequence of Barrett's Esophagus | Q61814005 | ||
| Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus | Q68122887 | ||
| The value of preoperative radiotherapy in esophageal cancer: results of a study of the E.O.R.T.C. | Q69254547 | ||
| Randomized clinical trial on the combination of preoperative irradiation and surgery in the treatment of esophageal carcinoma: report on 206 patients | Q69487537 | ||
| A comparison of multimodal therapy and surgery for esophageal adenocarcinoma | Q71164736 | ||
| Preoperative radiotherapy for carcinoma of the esophagus | Q71572381 | ||
| Concomitant analysis of the epidermal growth factor receptor family in esophageal cancer: overexpression of epidermal growth factor receptor mRNA but not of c-erbB-2 and c-erbB-3 | Q73062638 | ||
| Colonic interposition after esophagectomy for cancer | Q73066648 | ||
| Eliminating the cervical esophagogastric anastomotic leak with a side-to-side stapled anastomosis | Q73388258 | ||
| Proposal for improved staging criteria for carcinoma of the esophagus and cardia | Q73794187 | ||
| Chemoradiotherapy of locally advanced esophageal cancer: long-term follow-up of a prospective randomized trial (RTOG 85-01). Radiation Therapy Oncology Group | Q77424043 | ||
| Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer | Q77738544 | ||
| Extended transthoracic resection compared with limited transhiatal resection for adenocarcinoma of the esophagus | Q78551320 | ||
| Frequent homogeneous HER-2 amplification in primary and metastatic adenocarcinoma of the esophagus | Q79401515 | ||
| Expression of epidermal growth factor receptor in esophageal and esophagogastric junction adenocarcinomas: association with poor outcome | Q79522451 | ||
| Comparing outcomes after transthoracic and transhiatal esophagectomy: a 5-year prospective cohort of 17,395 patients | Q79950185 | ||
| Her-2/neu in barrett esophagus: a comparative study between histology, immunohistochemistry, and fluorescence in situ hybridization | Q80165950 | ||
| The role of overdiagnosis and reclassification in the marked increase of esophageal adenocarcinoma incidence | Q81290009 | ||
| Cetuximab with concurrent chemoradiation for esophagogastric cancer: assessment of toxicity | Q81547151 | ||
| Preoperative therapy for esophageal cancer | Q83572036 | ||
| Aurora kinase inhibitors in preclinical and clinical testing | Q83589206 | ||
| Survival in lymph node negative adenocarcinoma of the esophagus after R0 resection with and without neoadjuvant therapy: evidence for downstaging of N status | Q83936521 | ||
| Increased CDX2 and decreased PITX1 homeobox gene expression in Barrett's esophagus and Barrett's-associated adenocarcinoma | Q28282119 | ||
| Tumour amplified kinase STK15/BTAK induces centrosome amplification, aneuploidy and transformation | Q28285317 | ||
| Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer | Q29619394 | ||
| Genetic differences between adenocarcinomas arising in Barrett's esophagus and gastric mucosa | Q30307786 | ||
| Silencing of MGMT expression by promoter hypermethylation in the metaplasia-dysplasia-carcinoma sequence of Barrett's esophagus | Q30412980 | ||
| DNA hypermethylation regulates the expression of members of the Mu-class glutathione S-transferases and glutathione peroxidases in Barrett's adenocarcinoma | Q30436675 | ||
| Darpp-32: a novel antiapoptotic gene in upper gastrointestinal carcinomas | Q30437615 | ||
| Hypermethylation and loss of expression of glutathione peroxidase-3 in Barrett's tumorigenesis | Q30438403 | ||
| Malignant progression in Barrett's esophagus: pathology and molecular biology | Q30842376 | ||
| Coamplification and coexpression of GRB7 and ERBB2 is found in high grade intraepithelial neoplasia and in invasive Barrett's carcinoma | Q31114947 | ||
| Downregulation of TS, DPD, ERCC1, GST-Pi, EGFR, and HER2 gene expression after neoadjuvant three-modality treatment in patients with esophageal cancer | Q31150414 | ||
| Preoperative radiotherapy in esophageal carcinoma: a meta-analysis using individual patient data (Oesophageal Cancer Collaborative Group). | Q32060428 | ||
| Molecular determinants in targeted therapy for esophageal adenocarcinoma | Q33243542 | ||
| Three-tiered risk stratification model to predict progression in Barrett's esophagus using epigenetic and clinical features | Q33326627 | ||
| Frequent overexpression of Aurora Kinase A in upper gastrointestinal adenocarcinomas correlates with potent antiapoptotic functions | Q33647697 | ||
| Persistent association of nailfold capillaroscopy changes and skin involvement over thirty-six months with duration of untreated disease in patients with juvenile dermatomyositis. | Q33694649 | ||
| Expression of t-DARPP mediates trastuzumab resistance in breast cancer cells | Q33743601 | ||
| Molecular biology of esophageal cancer. | Q34020458 | ||
| Esophageal carcinoma: depth of tumor invasion is predictive of regional lymph node status | Q34462598 | ||
| Aurora kinases: new targets for cancer therapy | Q34587271 | ||
| A meta-analysis of randomized controlled trials that compared neoadjuvant chemoradiation and surgery to surgery alone for resectable esophageal cancer | Q35143202 | ||
| Biomarkers of esophageal adenocarcinoma and Barrett's esophagus | Q35680678 | ||
| Oncogenic K-Ras signals through epidermal growth factor receptor and wild-type H-Ras to promote radiation survival in pancreatic and colorectal carcinoma cells. | Q35756960 | ||
| Epidermal growth factor receptor expression correlates with histologic grade in resected esophageal adenocarcinoma | Q35761590 | ||
| Preoperative chemoradiotherapy for oesophageal cancer: a systematic review and meta-analysis | Q35803550 | ||
| Vascular endothelial growth factor in esophageal cancer | Q35849980 | ||
| Cell and molecular biology of the small intestine: new insights into differentiation, growth and repair. | Q36036420 | ||
| Aurora kinases: shining lights on the therapeutic horizon? | Q36210257 | ||
| Drosophila Aurora A kinase is required to localize D-TACC to centrosomes and to regulate astral microtubules. | Q36324220 | ||
| Systematic overview of preoperative (neoadjuvant) chemoradiotherapy trials in oesophageal cancer: evidence of a radiation and chemotherapy dose response | Q36424588 | ||
| Mechanisms of disease: Oncogene addiction--a rationale for molecular targeting in cancer therapy | Q36559283 | ||
| Aurora-A and p16 polymorphisms contribute to an earlier age at diagnosis of pancreatic cancer in Caucasians | Q36627355 | ||
| Modeling oncogene addiction using RNA interference. | Q36840172 | ||
| Incidence of adenocarcinoma of the esophagus among white Americans by sex, stage, and age. | Q36841557 | ||
| Epidermal growth factor receptor tyrosine kinase inhibitor, erlotinib, and concurrent 5-fluorouracil, cisplatin and radiotherapy for patients with esophageal cancer: a phase I study | Q46827347 | ||
| Induction cisplatin and paclitaxel followed by combination chemoradiotherapy with 5-fluorouracil, cisplatin, and paclitaxel before resection in localized esophageal cancer: a phase II report | Q46898344 | ||
| Expression of carbonic anhydrase IX (CA IX), a hypoxia-related protein, rather than vascular-endothelial growth factor (VEGF), a pro-angiogenic factor, correlates with an extremely poor prognosis in esophageal and gastric adenocarcinomas | Q46958508 | ||
| A phase II study of gefitinib monotherapy in advanced esophageal adenocarcinoma: evidence of gene expression, cellular, and clinical response | Q46972228 | ||
| Expression of the intestinal marker Cdx2 in the columnar-lined esophagus with and without intestinal (Barrett's) metaplasia | Q47418093 | ||
| A prospective randomized comparison of transhiatal and transthoracic resection for lower-third esophageal carcinoma. | Q50931006 | ||
| Multicenter phase II study of irinotecan, cisplatin, and bevacizumab in patients with metastatic gastric or gastroesophageal junction adenocarcinoma. | Q51776237 | ||
| Phase II trial of erlotinib in gastroesophageal junction and gastric adenocarcinomas: SWOG 0127. | Q51779657 | ||
| Molecular dissection of 17q12 amplicon in upper gastrointestinal adenocarcinomas. | Q54591709 | ||
| K-ras codon 12 mutations in Barrett's oesophagus and adenocarcinomas of the oesophagus and oesophagogastric junction | Q56591148 | ||
| Amplification and over-expression of theEGFR anderbB-2 genes in human esophageal adenocarcinomas | Q57421139 | ||
| Adenocarcinoma of the gastroesophageal junction: influence of esophageal resection margin and operative approach on outcome | Q57846070 | ||
| Symptomatic Gastroesophageal Reflux as a Risk Factor for Esophageal Adenocarcinoma | Q58204833 | ||
| Early esophageal cancer: pattern of lymphatic spread and prognostic factors for long-term survival after surgical resection | Q58484694 | ||
| Aurora kinase A inhibition leads to p73-dependent apoptosis in p53-deficient cancer cells | Q36984707 | ||
| Genetic polymorphisms of VEGF, interactions with cigarette smoking exposure and esophageal adenocarcinoma risk | Q37090696 | ||
| The aurora kinase A regulates GSK-3beta in gastric cancer cells | Q37096754 | ||
| Oncogene addiction | Q37152445 | ||
| Oncogene addiction versus oncogene amnesia: perhaps more than just a bad habit? | Q37152449 | ||
| Perioperative anesthetic management for esophagectomy | Q37154390 | ||
| Epidermal growth factor receptor-directed therapy in esophageal cancer | Q37162929 | ||
| Esophageal adenocarcinoma arising in Barrett esophagus | Q37169303 | ||
| Acid, bile, and CDX: the ABCs of making Barrett's metaplasia | Q37192028 | ||
| Treatment results of adenocarcinoma of the gastroesophageal junction | Q37211127 | ||
| The Aurora kinase family in cell division and cancer. | Q37228956 | ||
| Epidermal growth factor receptor kinase domain mutations in esophageal and pancreatic adenocarcinomas | Q37252270 | ||
| Tumor dormancy and oncogene addiction | Q37286246 | ||
| Targeting aurora kinase with MK-0457 inhibits ovarian cancer growth. | Q37398815 | ||
| Aurora kinase inhibitors | Q37445283 | ||
| Current Opinion on Optimal Treatment Choices in First-line Therapy for Advanced or Metastatic Colorectal Cancer: Report From the Adelaide Colorectal Tumour Group Meeting; Stockholm, Sweden; September 2008. | Q37681185 | ||
| Surgical therapy of oesophageal carcinoma | Q37950431 | ||
| Simultaneous blockade of the epidermal growth factor receptor/mammalian target of rapamycin pathway by epidermal growth factor receptor inhibitors and rapamycin results in reduced cell growth and survival in biliary tract cancer cells | Q39840571 | ||
| Both t-Darpp and DARPP-32 can cause resistance to trastuzumab in breast cancer cells and are frequently expressed in primary breast cancers. | Q39870542 | ||
| The Aurora kinase inhibitor VE-465 has anticancer effects in pre-clinical studies of human hepatocellular carcinoma | Q39893220 | ||
| Bile acids induce overexpression of homeobox gene CDX-2 and vascular endothelial growth factor (VEGF) in human Barrett's esophageal mucosa and adenocarcinoma cell line. | Q40081597 | ||
| Activation of downstream epidermal growth factor receptor (EGFR) signaling provides gefitinib-resistance in cells carrying EGFR mutation | Q40176065 | ||
| Heparin-binding EGF-like growth factor is an early response gene to chemotherapy and contributes to chemotherapy resistance | Q40227623 | ||
| Phase I/II study of trastuzumab, paclitaxel, cisplatin and radiation for locally advanced, HER2 overexpressing, esophageal adenocarcinoma | Q40271053 | ||
| Targeting the epidermal growth factor receptor by erlotinib (Tarceva) for the treatment of esophageal cancer | Q40363293 | ||
| Trastuzumab, paclitaxel, cisplatin, and radiation for adenocarcinoma of the esophagus: a phase I study. | Q40463186 | ||
| Monoclonal antibody to HER-2/neu receptor enhances radiosensitivity of esophageal cancer cell lines expressing HER-2/neu oncoprotein. | Q40475456 | ||
| ERBB2 amplifications in esophageal adenocarcinoma | Q40498835 | ||
| HER-2/neu gene amplification by FISH predicts poor survival in Barrett's esophagus-associated adenocarcinoma | Q40779159 | ||
| Is radiation therapy needed in the treatment of gastroesophageal junction adenocarcinoma? | Q42022302 | ||
| Neoadjuvant chemoradiotherapy for resectable esophageal carcinoma: a meta-analysis | Q42951422 | ||
| Phase II study of cetuximab in combination with FOLFIRI in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma (FOLCETUX study). | Q43604675 | ||
| Changing patterns in the incidence of esophageal and gastric carcinoma in the United States | Q43873434 | ||
| Pre-operative radiotherapy prolongs survival in operable esophageal carcinoma: a randomized, multicenter study of pre-operative radiotherapy and chemotherapy. The second Scandinavian trial in esophageal cancer | Q43956924 | ||
| Surgical resection with or without preoperative chemotherapy in oesophageal cancer: a randomised controlled trial | Q44017893 | ||
| Survival benefits from neoadjuvant chemoradiotherapy or chemotherapy in oesophageal carcinoma: a meta-analysis. | Q44022873 | ||
| Predictors of major morbidity and mortality after esophagectomy for esophageal cancer: a Society of Thoracic Surgeons General Thoracic Surgery Database risk adjustment model | Q44247929 | ||
| Outcomes after transhiatal and transthoracic esophagectomy for cancer | Q44448365 | ||
| Epidermal growth factor receptor, p53 mutation, and pathological response predict survival in patients with locally advanced esophageal cancer treated with preoperative chemoradiotherapy. | Q44705891 | ||
| Polymorphisms of the AURKA (STK15/Aurora Kinase) Gene and Breast Cancer Risk (United States). | Q45299793 | ||
| Multicenter phase II trial of preoperative induction chemotherapy followed by chemoradiation with docetaxel and cisplatin for locally advanced esophageal carcinoma (SAKK 75/02). | Q45998771 | ||
| En bloc esophagectomy reduces local recurrence and improves survival compared with transhiatal resection after neoadjuvant therapy for esophageal adenocarcinoma | Q46165349 | ||
| Bile acid alone, or in combination with acid, induces CDX2 expression through activation of the epidermal growth factor receptor (EGFR). | Q46316834 | ||
| Pilot study of gefitinib, oxaliplatin, and radiotherapy for esophageal adenocarcinoma: tissue effect predicts clinical response | Q46322646 | ||
| Prevalence and location of nodal metastases in distal esophageal adenocarcinoma confined to the wall: implications for therapy | Q46605436 | ||
| Surgery alone versus chemoradiotherapy followed by surgery for resectable cancer of the oesophagus: a randomised controlled phase III trial. | Q46675470 | ||
| P433 | issue | 12 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | adenocarcinoma | Q356033 |
| P304 | page(s) | 3304-3314 | |
| P577 | publication date | 2010-03-19 | |
| P1433 | published in | Digestive Diseases and Sciences | Q15716711 |
| P1476 | title | Esophageal adenocarcinoma: treatment modalities in the era of targeted therapy | |
| P478 | volume | 55 |
| Q53394190 | Association of HOTAIR expression with PI3K/Akt pathway activation in adenocarcinoma of esophagogastric junction. |
| Q54342465 | Clinicopathological and prognostic significance of epidermal growth factor receptor overexpression in patients with esophageal adenocarcinoma: a meta-analysis. |
| Q37593285 | Integrated molecular analysis reveals complex interactions between genomic and epigenomic alterations in esophageal adenocarcinomas |
| Q35043996 | Prognostic importance and therapeutic implications of PAK1, a drugable protein kinase, in gastroesophageal junction adenocarcinoma |
| Q35159395 | Screening and selection of peptides specific for esophageal cancer cells from a phage display peptide library |
| Q27026253 | Signaling pathways in the molecular pathogenesis of adenocarcinomas of the esophagus and gastroesophageal junction |
| Q36763844 | Three-gene immunohistochemical panel adds to clinical staging algorithms to predict prognosis for patients with esophageal adenocarcinoma |
Search more.